<DOC>
	<DOCNO>NCT00967850</DOCNO>
	<brief_summary>The purpose study determine efficacy safety intravitreal injection bevacizumab High Myopia´s choroidal neovascularization versus standard treatment Photodynamic therapy .</brief_summary>
	<brief_title>Efficacy Safety Intravitreal Bevacizumab Treatment Choroidal Neovascular Membranes Associated High Myopia</brief_title>
	<detailed_description>Bad response choroidal neovascularization High myopia Photodynamic therapy , current approve treatment pathology , high incidence pathology patient , together great functional impact vision foster search new therapeutic strategy . Intravitreal bevacizumab already test small series patient choroidal neovascularization associate high myopia , whether first treatment option failure photodynamic therapy good result . In published series improvement visual acuity describe 1-2 injection , reduction macular edema good safety profile . The lack publish trial describe efficacy frequency treatment pathology main reason trial .</detailed_description>
	<mesh_term>Myopia</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Patient least 18 year old High Myopia one following : 6 sphere diopter study eye Axial length eye great 26 millimeter Active subfoveal/juxtafoveal choroidal neovascularization confirm Fluorescein angiography Ocular coherence tomography . Visual acuity loss le 6 month evolution relate neovascular lesion , state investigator´s opinion . Patients previously treat Photodynamic therapy allow participate long last treatment perform 3 month upon enter study . Signed informed consent . Signed data protection consent . Women childbearing potential must provide negative pregnancy test inclusion must commit use contraceptive treatment whole study . Previous vitrectomy surgery study eye . Tractional maculopathy and/or epiretinal membrane evaluate Ocular coherence tomography . Opacities may allow correct fundus assessment . Lack integrity posterior lens capsule pseudoaphakic patient . Patients may want/be able complete study , base investigator opinion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>High Myopia</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Photodynamic therapy</keyword>
</DOC>